Compounds > 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine
Page last updated: 2024-09-03

1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine and Glucose Intolerance

1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine has been researched along with Glucose Intolerance in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Alexandrou, E; Andrew, M; Backeljauw, P; Dauber, A; Hwa, V; Muthuvel, G; Tyzinski, L1

Other Studies

1 other study(ies) available for 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine and Glucose Intolerance

ArticleYear
Five-Year Therapy with Recombinant Human Insulin-Like Growth Factor-1 in a Patient with PAPP-A2 Deficiency.
    Hormone research in paediatrics, 2023, Volume: 96, Issue:5

    Topics: Glucose; Glucose Intolerance; Humans; Hyperinsulinism; Insulin-Like Growth Factor I; Male; Pseudotumor Cerebri; Recombinant Proteins

2023